EUZ Stock Overview
Manufactures and sells isotope technology components worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EUZ from our risk checks.
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €37.93 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1.33 |
| 11 Month Change | -14.92% |
| 3 Month Change | -14.13% |
| 1 Year Change | -4.22% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| EUZ | BG Medical Equipment | BG Market | |
|---|---|---|---|
| 7D | -4.4% | -2.4% | -0.5% |
| 1Y | -4.2% | 13.2% | 10.9% |
Return vs Industry: EUZ underperformed the BG Medical Equipment industry which returned 13.2% over the past year.
Return vs Market: EUZ underperformed the BG Market which returned 10.9% over the past year.
Price Volatility
| EUZ volatility | |
|---|---|
| EUZ Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BG Market | 7.8% |
| 10% least volatile stocks in BG Market | 2.5% |
Stable Share Price: EUZ has not had significant price volatility in the past 3 months compared to the BG market.
Volatility Over Time: EUZ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,085 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.
Eckert & Ziegler SE Fundamentals Summary
| EUZ fundamental statistics | |
|---|---|
| Market cap | €795.88m |
| Earnings (TTM) | €37.68m |
| Revenue (TTM) | €277.71m |
21.1x
P/E Ratio2.9x
P/S RatioIs EUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZ income statement (TTM) | |
|---|---|
| Revenue | €277.71m |
| Cost of Revenue | €144.30m |
| Gross Profit | €133.42m |
| Other Expenses | €95.74m |
| Earnings | €37.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 1.81 |
| Gross Margin | 48.04% |
| Net Profit Margin | 13.57% |
| Debt/Equity Ratio | 8.6% |
How did EUZ perform over the long term?
See historical performance and comparison